After Fine, Botox Awaits F.D.A. Approval for Migraine

Allergan agreed to pay $600 million for Botox’s marketing getting ahead of approved uses. But the F.D.A. will soon decide on its effectiveness for chronic migraines.

MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment In Open-Label Trial And Completion Of ...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX. At this time, all patients have been ...

Zogenix files for IPO on strength of migraine treatment

The San Diego biotechnology company is hoping to raise as much as $90 million in an initial public stock offering.

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of ...

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEXâ¢.

License Agreement for Breakthrough Pain Relief Product Drives Launch of Renewal Technologies

PHOENIX -- Bob Gottschalk believes that lightning can strike twice. In fact, with the launch of his new business venture -- Renewal Technologies -- he's betting on it.